A Comprehensive Cancer Center Designated by the National Cancer Institute

For Patients

University of Chicago Phase II Consortium (UC P2C)

The University of Chicago Phase II Consortium (UC P2C) is a collaborative academic/community partnership funded by the National Cancer Institute to conduct early phase oncology clinical trials.

Clinical Trials

The National Cancer Institute (NCI) defines clinical trials as research studies that test how well new medical approaches work in people. Each UC P2C study answers a scientific question and tries to find better ways to prevent, screen for, diagnose, or treat cancer. People who take part in UC P2C cancer clinical trials receive up-to-date care from the foremost medical experts at one of the country’s top cancer centers. Patients benefit by having access to clinical trials in their own communities, with academic center support for limited-access procedures. They also have an opportunity to contribute to the knowledge and progress against cancer in a way that may help other patients. The UC P2C offers unique clinical trials at each one of our 11 insitutional member sites.

UC P2C Institutional Members and their Websites

For More Information

Mary A. Sherrell, MA, Director of Multi-Institutional Research Services msherrell@medicine.bsd.uchicago.edu (773)702-9856